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Abstract
Background:  Few studies have evaluated patient-reported outcomes in connection with a
primary event of deep venous thrombosis, partly due to a lack of disease-specific measures. The
aim here was to develop a disease-specific health-related quality of life (HRQL) measure, the deep
venous thrombosis quality of life questionnaire (DVTQOL), for patients with recent exposition and
treatment of proximal deep venous thrombosis.
Methods: A total of 121 consecutive outpatients (50 % males; mean age 61.2 ± 14 years) treated
with warfarin (Waran®) for symptomatic proximal deep venous thrombosis were included in the
study. Patients completed the SF-36, EQ-5D and the pilot version of the DVTQOL.
Results: Items having: high ceiling and floor effect, items with lower factor loadings than 0.50 and
items loading in several factors were removed from the pilot version of DVTQOL. In addition,
overlapping and redundant items identified by the Rasch analysis were excluded. The final
DVTQOL questionnaire consists of 29 items composing six dimensions depicting problems with:
emotional distress; symptoms (e.g. pain, swollen ankles, cramp, bruising); limitation in physical
activity; hassle with coagulation monitoring; sleep disturbance; and dietary problems. The internal
consistency reliability was high (alpha value ranged from 0.79 to 0.93). The relevant domains of the
SF-36 and EQ-5D significantly correlated with DVTQOL, thereby confirming its construct validity.
Conclusions: The DVTQOL is a short and user-friendly instrument with good reliability and
validity. Its test-retest reliability and responsiveness to change in clinical trials, however, must be
explored.
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Background
Health-related quality of life is significantly impaired in
individuals with vascular disease[1,2]. Besides the risk of
acute pulmonary embolism DVT is associated with a vari-
ety of symptoms, generally referred to as post-thrombotic
syndrome, which restricts patients' daily activities [3-5].
Patients report problems with functioning, low levels of
energy, sleep disturbance, pain and limitations in physical
mobility that were evaluated by the Nottingham Health
Profile (NHP). In a long-term outcomes study of DVT, it
was shown that symptoms in the leg, such as pain, swell-
ing, ulceration and discoloration, affected patients' per-
ception of HRQL as measured by the Short Form Health
Survey (SF-36) [6,7]. Patients with symptoms reported
low levels of physical functioning and severely impaired
role functioning. Moreover, there are a number of charac-
teristics of current oral anticoagulation therapies that can
potentially induce dissatisfaction and reduce HRQL.
Among these are the necessity for frequent doctor visits for
regular blood testing, lifestyle limitations, including
restrictions on diet and activities, and possible worry
about bleedings. Thus, the practical and psychological
demand of such therapy has negative effects on patients'
perceptions of their HRQL[8,9].
Both general and disease-targeted questionnaires are help-
ful in increasing the understanding of health-related qual-
ity of life outcomes in patients after a deep-vein
thrombosis event. General instruments include health
profiles and assessments of the overall health state. They
can be used to compare the relative burden of illness in
the general population and between different diseases.
Disease-targeted instruments, on the other hand, may be
used to elucidate specific domains of particular impor-
tance to the patient.
The general knowledge about the burden of illness in this
group of patients is poor and information on disease- and
therapy-related HRQL is sparse. In clinical practice, the
value of being able to measure HRQL and satisfaction
with care that is not adequately captured by traditional
measures of morbidity and mortality is self-evident, but
most measures are either limited by their narrow focus as
they are restricted to patients with varicose veins or leg
ulcer [10,11] or they lack evidence of reliability and valid-
ity. For routine monitoring of outcomes in chronic
venous disorders, the VEINES-QOL questionnaire[12],
and Mathias and colleagues' [13] measure for acute ili-
ofemoral deep venous thromboses, have been developed.
For recent experience of DVT, however, there is no ade-
quate instrument available for use in clinical trials. To
meet this need, a new instrument measuring health- and
treatment-related quality of life in patients with recent
experience of DVT was developed. Data on self-perceived
burden of disease and health status are also presented.
Methods
Patients and Methods
Consecutive male and female patients between 18 and 80
years with a verified diagnosis of deep venous thrombosis
(ultrasound or phlebography) were recruited from local
anticoagulation services at the Sahlgrens' University Hos-
pital, Frölunda, Lundby and Vasa Hospitals in Gothen-
burg, Sweden, between March 1999 and March 2000.
Patients were treated with warfarin (Waran®) between four
weeks and six months. Patients were identified in connec-
tion with a routine monitoring visit at the hospital labo-
ratory. This was a one-visit open study. Those with other
significant medical or surgical diseases such as malig-
nancy, chronic obstructive lung disease, heart failure or
any major psychiatric illness or dementia, were excluded.
Age, gender, smoking and alcohol habits were recorded.
Medical history, concomitant medication and symptom
severity (mild, moderate, severe) were noted. Questions
were also asked about patient's socio-economic situation.
Patients gave their written consent to participate and were
free to discontinue their participation in the study at any
time. The study was reviewed and approved by the
regional Ethics Committee of Gothenburg University. The
aim was to recruit 150 patients with verified DVT.
Item generation for the DVTQOL
All discussions and interviews were done in Sweden in a
Swedish population. Items for the new DVTQOL ques-
tionnaire were identified from individual interviews with
DVT patients. Specialists widely experienced in anticoagu-
lation practice (physicians and nurses) were consulted,
and a thorough review of the medical literature regarding
patient-reported outcomes of venous leg disorders was
conducted. We searched in the Medline Database and
Swedish Physician Journal for publications written in
English between 1991 and 2003. We also searched for
information in patient information pages on the Web
(e.g. American Venous Forum). Patients were asked to
identify issues and problems they had as a result of their
illness. For each item, they rated the importance (impor-
tant/not important). The results were expressed as fre-
quency, i.e. the proportion of patients that experienced a
particular item. Items included physical, emotional and
sleep issues as well as symptoms and hassle with treat-
ment. Even though several of the items were specific to
each individual, there was considerable overlap in the
item pool. A total of 65 questions were generated that
were carefully formatted for gender, clarity and interpret-
ability. Responses were arranged on a seven-point Likert
scale to assess how much or how often the item described
the feelings of the patient: degree of distress (not at all,
minor, mild, moderate, moderate severe, severe,
extremely severe) and frequency of the problem (never,
hardly ever, occasionally, sometimes, frequently, most of
the time, all of the time). Seven-point scales are supposedHealth and Quality of Life Outcomes 2004, 2:30 http://www.hqlo.com/content/2/1/30
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to be easier for the patients to learn and understand and
changes are easier to interpret as compared to visual ana-
logue scales[14]. Summary scores for each of the six
domains can be calculated (maximum range between 30
and 210). The higher the score, the more discomfort, dis-
tress, inconvenience and hassle patients feel. Once this
preliminary set of items was developed, we administered
the instrument in "face to face interviews" with eight
patients. A clinician evaluation of the relevance of the 65
items selected according to the principles described above
was also made. All items were written and answered in
Swedish.
Patient-Reported Outcomes (PRO) instruments
Patients completed the DVTQOL-65 together with two
generic health-related quality of life measures, the Swed-
ish translations of the Short Form Survey, SF-36 (SF-36)
and the EuroQol of life (EQ-5D), at their next routine
visit, preferable within a week or two.
The SF-36 instrument contains 36 items that measure
eight dimensions: Physical Functioning, Role limitation
due to Physical health problems, Bodily Pain, General
Health perceptions, Vitality, Social Functioning, Role lim-
itations due to Emotional problems and general Mental
Health. Item scores for each dimension are coded,
summed and transformed to a scale from 0 to 100, with
higher scores indicating better self-perceived health. The
reliability and validity of the (Swedish) SF-36 is well doc-
umented [15,16] in a variety of different patient groups,
including patients with vascular diseases[17].
EQ-5D is a measure of health status developed for use in
evaluating health outcomes and healthcare[18,19]. It pro-
vides a simple descriptive profile and derives a single
index value for heath status on which full health is
assigned a value of 1 and death a value of 0 (DSI). EQ-5D
describes health status in terms of five dimensions: Mobil-
ity, Self-care, Usual activity, Pain/Discomfort and Anxiety/
Depression. Each dimension has three possible levels: 1-
No problem, 2-Some problem and 3-Extreme problem.
Data management
Patients completed the questionnaires, using an Apple
Newton hand-held electronic data capture device, prior to
the actual laboratory visit in order to avoid potential bias
induced by discussions on disease and dosing procedures.
For compliance with study regimens, the questionnaires
were administrated at the study site under the supervision
of the study nurse. Medical information and clinical data
were entered into electronic case report forms by the
investigator and the study nurse, using a pc laptop com-
puter. Computer-administrated electronic data collec-
tions are accepted and desirable for assessments of health-
related quality of life in clinical studies since they yield
high-quality data and no missing data[20]. It was well
accepted among patients, the investigator and the study
nurse.
Psychometric evaluation of the DVTQOL
Item reduction
Items with the following characteristics were considered
for removal: 1) Semantically identical or very similar
items; 2) items with a high ceiling or floor effect, i.e. items
where more than 50% endorsed "no discomfort at all" or
"extremely severe discomfort", "none of the time" or "all
of the time"; 3) items measuring a different construct, i.e.
with a low squared multiple correlation (r<0.5) with the
other items; 4) items that showed redundancy of measure-
ment by too high a correlation (alpha >0.95). Before
items were removed, the clinical importance as judged by
the physician and nurse in charge of the study was dis-
cussed, i.e. content validity was taken into consideration
as well.
Rasch methodology
The most recent application of this methodology was in
outcomes research and in instrument develop-
ment[21,22]. In this study, the Rasch methodology was
used to reduce the number of items in the item pool, as
this was recommended in previous studies [23,24]. In the
Rasch model each item is defined by a difficulty or loca-
tion parameter. It assumes that the probability of a given
respondent to give a "correct" answer to a particular item
is a logistic function of the relative distance between the
item location parameter and the respondent location
parameter [25]. Rasch methodology was utilised to reduce
redundant items. Items that were too "easy" or too "diffi-
cult" to endorse based on the person-item distribution
and items with the same "difficulty" level were also
excluded.
Factor analysis
After a first item reduction the data were re-analysed in
order to explore how the selected questions were com-
bined into relevant domains. Hence, an exploratory factor
analysis was undertaken to identify the underlying con-
cepts or domains. For this purpose a principal compo-
nents factor analysis with varimax orthogonal rotation
was utilised. Items with factor loadings above 0.50 were
retained.
Internal consistency reliability
Cronbach's alpha[26] was used to assess the internal con-
sistency reliability. A moderate to high alpha coefficient
suggests that the items within a domain measure the same
construct, which supports the construct validity as well.
Alpha scores between 0.70 and 0.95 are desirable to allow
for individual comparisons.Health and Quality of Life Outcomes 2004, 2:30 http://www.hqlo.com/content/2/1/30
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Construct validity
The SF-36 and EQ-5D were used to compare whether con-
ceptually similar domains had higher correlations than
conceptually unrelated domains. This was tested using
correlation coefficients.
Statistical methods
Descriptive statistics (i.e. frequencies, means, standard
deviations) were used to characterise the demographic
data. Pearson's correlation was also used to test the inter-
scale correlations of the DVTQOL. On the basis of previ-
ous experience, strong correlations were considered to be
above 0.40. P-values were adjusted for multiplicity (Bon-
ferroni)[27]; the significance level was p < 0.0005. All sta-
tistical analyses were made using SAS 8.1 software[28].
The Winstep software was used for the Rasch analysis [29].
The data quality was excellent in the present study since
there were no missing data for any item on the quality of
life questionnaires in the study.
Results
From a total of 351 enrolled patients, 121 (50% males;
mean age 61.2 ± 14 years) with verified deep venous
thrombosis (DVT) were included in the study. Patients'
ages ranged from 23–79; 31% were under the age of 65.
All patients were treated with warfarin (Waran®) for at
least four weeks. About 20% of the enrolled patients
refused or were not interested in participating in the study.
These individuals, half women, were elderly people (70 ±
12 years). Two individuals discontinued participation in
the study, one due to severe asthma and one without giv-
ing any specific reason. Clinical signs and symptoms
(mild or moderate) were reported by 35 %. Patients were
slightly overweight, with a body mass index between 25
and 26.9. Regarding comorbidity, the most common dis-
eases, other than DVT, were hypertension, diabetes,
hyperlipemi and cerebral infarction. Patient characteris-
tics and clinical data are summarised in Table 1. Table 1
shows also the mean values of SF-36 by dimension for the
DVT and Swedish normative values for the general
population. DVT patients reported worse health status in
Table 1: Demographic and clinical characteristics (N = 121)
Variables
Age: Mean (SD) 61.2 (14.0)
n%
Gender: Male 61 50.4
Smoker: Yes 24 19.8
Alcohol: Never 9 7.4
Occasionally 109 90.1
Daily 3 2.5
No symptoms 78 64.5
Clinical signs and symptoms: Mild 24 19.8
Moderate 18 14.9
Severe 1 0.8
Marital status: Married 77 63.6
Education: High school 70 57.9
University 52 43.0
Employment: Full time 32 26.4
Part time 8 6.6
Retired and Unemployed 81 67.0
Sick leave during last 3 months Yes 23 19.0
SF-36 DVT* Norm†
Physical function PF 67.3 87.9
Role physical RP 68.0 83.2
Bodily pain BP 71.6 74.8
General health GH 62.9 75.8
Vitality VT 63.7 68.8
Social function SF 87.6 88.6
Role emotional RE 73.8 85.7
* Deep Venous Thrombosis † Swedish normative values for the general population (n = 8930)Health and Quality of Life Outcomes 2004, 2:30 http://www.hqlo.com/content/2/1/30
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all dimensions of the SF-36 than the Swedish general pop-
ulation. In all dimensions, except for Social functioning
and Bodily Pain, the difference was larger than 5 score
units, which is considered to be clinically relevant[30].
When we matched the SF-36 scores for the age groups, eld-
erly patients (>75 years) reported a similar health status as
the general age-matched population. Women reported
lower scores than men, specifically in the Pain domain.
Psychometric evaluation of the DVTQOL
Factor analysis
Exploratory factor analysis yielded six distinct factors
denoting emotional distress: symptoms; limitation in
physical activity; hassle with coagulation monitoring;
sleep disturbance; and dietary problems. The factors with
their respective factor loadings are presented in Table 2.
Items with factor loadings above 0.50 were retained. Item
nr. 16 had strong loading on both factor one (emotional
distress) and three (limitation in physical activity); how-
ever, this item was retained because of its clinical impor-
tance as judged by clinicians and patients. In conclusion,
Table 2: Exploratory factor analysis of the final DVTQOL
Factors
I t e m s 123456
Emotional distress
1. Feel weak or feeble 0.66* 0.15 0.15 0.11 0.38 0.02
2. Feel anxious about your health 0.68* 0.25 0.31 0.22 -0.02 0.35
3. Feel tired 0.62* 0.14 0.18 0.12 0.34 0.07
4. Unable to live as you'd like 0.81* 0.15 0.26 0.13 -0.01 0.21
5. Feel anxious about the future 0.80* 0.08 0.24 0.06 -0.06 0.26
6. Feel irritated 0.71* 0.26 -0.04 0.05 0.18 -0.12
7. Feel frustrated and impatient 0.82* 0.12 0.22 0.15 0.18 0.10
Symptoms
8. Pain in the leg 0.19 0.64* 0.35 0.04 0.22 0.03
9. Swollen ankles 0.18 0.65* 0.13 -0.07 0.12 -0.03
10. 'Sense of fatigue' in the leg 0.32 0.74* 0.23 0.14 0.15 0.07
11. Cramp in the leg -0.04 0.62* 0.02 0.04 0.10 -0.03
12. Tension in the muscles 0.21 0.66* 0.17 -0.04 -0.01 0.12
13. Numbness, crawling or pricking sensation 0.10 0.72* 0.33 0.09 -0.06 0.13
14. Bruising on the leg -0.06 0.54* -0.23 0.18 0.39 0.04
15. 'Feeling of heaviness' in the leg 0.35 0.66* 0.22 0.03 0.27 -0.01
Limitation in physical activity
16. Stumbling, falling or cutting yourself 0.42 0.07 0.50* 0.04 0.22 0.12
17. Go for long walks 0.23 0.33 0.79* 0.12 0.15 -0.03
18. Stand still for long periods 0.22 0.26 0.64* 0.08 0.11 0.13
19. Refrain from physical activities 0.10 0.14 0.83* 0.14 0.15 0.03
20. Discomfort when walking up stairs 0.39 0.26 0.64* -0.02 0.15 -0.08
Hassle with monitoring
21. Irritation due to monitoring 0.13 0.06 0.09 0.89* -0.00 0.09
22. Inconvenience due to monitoring 0.17 0.09 0.10 0.92* 0.02 0.05
23. Refrain from doing things due to monitoring 0.14 0.00 0.08 0.94* -0.04 0.05
Sleep disturbance
24. Trouble getting to sleep 0.12 0.32 0.18 -0.08 0.78* 0.03
25. Wake up during the night 0.39 0.22 0.16 -0.06 0.75* 0.01
26. Not sleeping properly 0.15 0.07 0.23 0.03 0.78* 0.10
Dietary problems
27. Awareness of food and drink 0.04 0.05 0.04 0.07 0.12 0.76*
28. Avoid certain food or drink 0.11 0.06 -0.03 0.12 -0.02 0.84*
29. Ought to eat and drink 0.21 0.01 0.08 -0.03 0.03 0.89*
Explained variance 4.85 4.09 3.29 2.79 2.58 2.43
Proportion of explained variance % 16.5 14.0 11.2 9.5 8.8 8.3Health and Quality of Life Outcomes 2004, 2:30 http://www.hqlo.com/content/2/1/30
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the final DVTQOL consists of six domains and 29 items.
Internal consistency reliability was satisfactory (Table 3).
Each of the six dimensions had a similarly high Cron-
bach's alpha value ranging from 0.93 (hassle with moni-
toring) to 0.79 (dietary problems).
Interscale correlation
Conceptually related domains were significantly related
(Table 4). Symptoms significantly correlated to emotional
distress, limitation in physical activity and sleep
disturbance.
Construct validity
Associations between the DVTQOL and the SF-36 scores
(convergent validity) were all in the expected direction
(Table 5). All SF-36 domains except for Social Functioning
and the Mental Component Summary score significantly
correlated to all DVTQOL domains except dietary prob-
lems and hassle with monitoring. Correlations between
DVTQOL and EQ-5D are shown in Table 6. EQ-5D
mobility, anxiety/depression and pain domains signifi-
cantly correlated with all relevant DVTQOL domains.
Discussion
The present study was conducted to develop a new
patient-based measure of health-related quality of life for
use in individuals with acute DVT. In contrast to previous
measures, the DVTQOL focuses on the early symptoms
and problems related to anticoagulation management
that patients have after a recent DVT event.
Individual DVTQOL items showed sufficient variation in
the item pool that clearly grouped into six factors, reflect-
ing emotional distress, symptoms, limitation in physical
activity, hassle with coagulation monitoring, sleep distur-
bance and dietary problems. In the present study, the
mode of therapy was an important issue as 'living with
anticoagulation' is a true obstacle, as is the impact of the
disease per se.
The DVTQOL domains had a high degree of internal con-
sistency, confirming its reliability. DVTQOL correlated
with the relevant domains of SF-36 and EQ-5D, which
provides evidence on construct validity. Interestingly, the
DVTQOL hassle with monitoring domain significantly
correlated with the SF-36 general health and mental
health, indicating that mandatory visits to the clinic for
blood monitoring interact with the perception of general
health and emotional distress. Furthermore, patients
reported significantly decreased HRQL compared to the
general population as measured by the SF-36, regardless
of gender and age. This is in agreement with Beyth and
colleagues' finding [6] that patients report poorer percep-
tion of health, lower levels of physical functioning and
more severe role limitations due to DVT.
In conclusion, the DVTQOL is a valid and reliable instru-
ment for measuring HRQL in patients with recent DVT
and who are currently on oral anticoagulation treatment.
Recognising that instrument development and validation
are by no means a one-time event, its test-retest reliability
and responsiveness to change in clinical trials must be
evaluated.
This study was funded by AstraZeneca R&D Mölndal,
Sweden




Limitation in physical activity 0.86
Hassle with monitoring 0.93
Sleep disturbance 0.83
Dietary problems 0.79
Table 4: Interscalecorrelations between DVTQOL domains
Domains Emotional 
distress

















0.32 0.18 0.24 1.00
Sleep 
disturbance
0.45 0.50 0.48 0.04 1.00
Dietary 
problems
0.33 0.15 0.16 0.16 0.15 1.00Health and Quality of Life Outcomes 2004, 2:30 http://www.hqlo.com/content/2/1/30
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Conclusions
The DVTQOL is a short and user-friendly instrument with
good reliability and validity. Its test-retest reliability and
responsiveness to change in clinical trials, however, must
be explored.
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